Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis and risk of leukemia transformation. There is evidence to suggest the participation of immune system deregulation in MDS pathogenesis. Interleukin-32 (IL-32) is a newly described multifunctional cytokine reported as an important mediator in autoimmune and inflammatory disorders. In the present study, we reported the expression of IL32 and IL32 transcript variants (α, β, γ and δ) in peripheral blood CD3 + cells from healthy controls and MDS patients. Methods: CD3 + cells were isolated by immunomagnetic cell sorting from thirty-nine untreated MDS patients and twenty-nine healthy donors. Gene expression was evaluated by quantitative PCR. For statistical analysis, Mann-Whitney test, Kruskal-Wallis test with Dunns post test and Log-rank (Mantel-Cox) were used, as appropriate. A p value <0.05 was considered statistically significant.
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Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of neoplasms characterized by dysplastic, ineffective blood cell production and risk of transformation to acute leukemia [1] . Clinical and immunological evidence suggest an association between immune system dysfunction and the pathogenesis of MDS [2, 3] . Autoimmune features are described in the early stage (low-risk) of disease, such as activated cytotoxic T lymphocytes [4] , lower number of regulatory T cells (Tregs), increased Th17, B-cell dysfunction, elevated levels of TNF-α, IFN-γ and pro-apoptotic cytokines [5, 6] . On the other hand, in advanced stage (high-risk) disease, evasion of the immune system, reduction of function NK cells, increased Tregs, and low levels of apoptosis are found [7, 8] , and an immune deregulation could participate in the progression of MDS [9] .
IL-32, a newly described multifunctional cytokine produced mainly by T, NK and epithelial cells, has been reported as an important mediator in several autoimmune and inflammatory disorders [10, 11] . There are more than nine isoforms of IL-32 described in the GenBank Database [12] . The distinct effects of IL-32 have been reported for several isoforms. IL-32α has been reported as the most abundant transcript and the IL-32γ isoform as the longest transcript with most prominent biological activity [13] . Apart from the proinflammatory role of IL-32, the association of IL-32α with PKCε and STAT3 [14] or with FAK1 has been reported [15] , suggesting a possible role of this cytokine as an intracellular signaling mediator. Furthermore, the role of IL-32 in the production of regulatory cytokines has been described: IL-32β interacts with PKCδ and C/EBPα, which results in the production of IL-10 [16] , and IL-32γ is correlated with enhanced production of proinflammatory cytokines, such as IL-1β and IL-6 [17] . IL-32γ is also implicated in HIV immunosuppression [18] and tumoral growth inhibition [19] . The interaction between IL-32δ and IL-32β isoforms inhibits IL-10 production by IL-32β [20] , which suggests that other interactions between IL-32 isoforms may explain their multifunctional role [21] .
The expression of IL32 isoforms has not yet been described in MDS. Herein, we report IL32 and L32 transcript variant (α, β, γ and δ) mRNA levels in peripheral blood CD3 + cells from healthy controls and MDS patients. 
Methods
Patients and donors
Peripheral blood samples, collected from thirty-nine newly diagnosed MDS patients (18 males, 21 females) with an age range of 27-89 years (median age = 69) and 29 unrelated, random, and healthy individuals (median age = 39, range, 28-60) were analyzed. Patients that regularly attended the clinic with a confirmed diagnosis of MDS and that were untreated at the time of the study were included. Patients' characteristics are described in Table 1 . All healthy controls and patients provided informed written consent and the study was approved by the ethics committee of the University of Campinas (reference number 124/2005).
Peripheral blood CD3 + T isolation
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque gradient centrifugation (Sigma, St Louis, MO, USA). CD3 + T cells from PBMC were sorted using anti-CD3 monoclonal antibody and MACS® Magnetic Cell sorting technique (Miltenyi Biotec, Bergisch Gladbach, Germany).
Quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from sorted CD3 + cells using Illustra RNAspin Mini Kit (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) and cDNA was generated using RevertAid H Minus First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany), according . MDS patients were stratified using the WHO 2008 classification intro refractory anemia (RA)/refractory anemia with ringed sideroblasts (RARS)/refractory cytopenia with multilineage dysplasia (RCMD) groups and refractory anemia with excess blast-1 (RAEB-1)/refractory anemia with excess blast-2 (RAEB-2) groups. The "y" axis represents the relative gene mRNA expression. The numbers of subjects studied are indicated in the graph manufactures instructions. Quantitative PCR (qPCR) was performed with SYBR Green Master Mix PCR (MBI Fermentas) in an ABI 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with specific primers for IL32 and transcript variants (α, β, γ and δ) and HPRT1. Primers sequences and concentrations are described in Fig. 1 . The relative gene expression was calculated using the equation, 2 -ΔΔCT [22] . A negative 'No Template Control' was included for each primer pair. The dissociation protocol was performed at the end of each run to check for non-specific amplification. Three replicas were run on the same plate for each sample.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., San. Diego, CA, USA) or SAS System for windows 9.2 (SAS Institute, Inc., Cary, NC, USA). For comparisons, Mann-Whitney test was used for comparison between two groups and Kruskal Wallis test with Dunns post test was used for comparison between three groups. Univariate and multivariate Cox regression were used to estimate overall survival (OS) and event free survival (EFS). OS was defined as the time (in months) between the date of sampling and the date of death (for deceased patients) or last follow-up (for censored patients). EFS was defined as the time (in months) between the sampling and the date of the first event (death or MDS progression to a higher risk MDS category by WHO or to acute myeloid leukemia (AML) with myelodysplasiarelated changes) or last follow-up (for censored patients). A p value <0.05 was considered statistically significant. Fig. 2 ).
Results
Expression of IL32 in peripheral blood CD3 + T cells of patients with MDS
IL32α expression impact upon MDS progression
Despite not having observed a difference in IL32 expression between MDS patients and healthy donors, we investigated whether IL32 expression could impact the clinical outcome of patients with MDS. Using Cox regression analysis, we observed that high IL32α expression negatively impacted EFS by univariate analysis, along with male gender and increased age (all p < 0.05). Furthermore, multivariate analyses indicated that high IL32α expression, along with age, 
Discussion
We herein observed that the expression profile of IL32 and IL32 transcript variants IL32α, IL32β, IL32γ, and IL32δ, was similar in peripheral blood CD3 + cells from healthy donors compared to those from MDS patients. Notably, we described in our cohort that increased IL32α expression was an independent predictor for MDS disease progression. IL-32 overexpression has been described in head and neck squamous cell carcinoma and has been related to shorter survival, possibly due to the potential role of IL-32 in the metastatic process [23] . IL-32 has also been proposed as a lung adenocarcinoma prognostic biomarker, in which high IL-32 expression was associated with high grade disease and metastasis incidence [24, 25] . In clear cell renal cell carcinoma patients, IL-32 overexpression was associated with disease progression and poor overall survival, indicating that IL-32 may be a novel prognostic factor for predicting outcomes in this disease [26] . Similarly, IL-32 has been reported as a poor prognostic marker for gastric cancer [27, 28] . Using the lung cancer A549 cell line, IL-32 inhibition reduced cell viability, migration and invasion, whereas IL-32 overexpression increased migration and invasion, indicating that this protein participates in the malignant phenotype of lung cancer cells [24] .
In contrast, we also observed that total IL32 and IL32δ expression presented an opposite impact on EFS, highlighting the functional differences between IL-32 isoforms. Bak et al. [29] reported that IL-32θ attenuated the invasive and migratory potential by suppressing the epithelial-mesenchymal transition in colon cancer HT29 cell line, and provided evidence that IL-32θ apparently inhibits the progression and recurrence of colon cancer.
Conclusion
In conclusion, we observed that IL32 expression is not differently expressed in CD3 + cells from MDS patients; nevertheless IL32α has a potential role in disease progression. Future studies are necessary to verify the specific functions of IL-32 and to better characterize the different IL-32 isoforms in immune system deregulation during MDS development and progression. 
